Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 - Siouxland News - KMEG 14 and FOX 44

Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Abaxis, Inc.

Declares Quarterly Cash Dividend

UNION CITY, Calif., July 24, 2014 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the first fiscal quarter ended June 30, 2014.

First quarter overview:

  • Revenues of $47.5 million, up 10% over last year's comparable quarter.
  • Diluted EPS of $0.21, up 50% over last year's comparable quarter.

Revenues highlights:

  • Medical market revenues of $7.2 million, up 20% over last year's comparable quarter.
  • Veterinary market revenues of $39.4 million, up 8% over last year's comparable quarter.
  • North America revenues of $38.3 million, up 11% over last year's comparable quarter.
  • International revenues of $9.1 million, up 7% over last year's comparable quarter.
  • Total medical and veterinary reagent disc revenues of $26.9 million, up 18% over last year's comparable quarter.
  • Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.4 million, up 55% over last year's comparable quarter.

Other financial highlights:

  • Income from operations of $7.4 million, up 60% over last year's comparable quarter.
  • Cash, cash equivalents and investments as of June 30, 2014 of $125.7 million, an increase of $4.5 million from March 31, 2014.
  • Cash dividend of $0.10 per share paid during the first quarter of fiscal 2015.

Dividend Declared

Abaxis today announced that its Board of Directors declared a quarterly dividend of $0.10 per common share to be paid on September 17, 2014, to all shareholders of record as of the close of business on September 3, 2014. 

Quarterly Results

For the fiscal quarter ended June 30, 2014, Abaxis reported revenues of $47.5 million, as compared with revenues of $43.2 million for the comparable period last year, an increase of 10 percent.  Revenues from sales of instruments, which include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers, decreased by $1.1 million, or 12 percent, compared to the same period last year.  Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests, increased by $3.7 million, or 12 percent, compared to the same period last year.  Abaxis reported net income of $4.7 million for the fiscal quarter ended June 30, 2014, compared to $3.2 million for the fiscal quarter ended June 30, 2013.  Abaxis' effective tax rate in the quarter ended June 30, 2014 was 37 percent, compared to 36 percent for the same period last year.  Abaxis reported diluted net income per share of $0.21 (calculated based on 22,637,000 shares) for the three-month period ended June 30, 2014, compared to $0.14 per share (calculated based on 22,571,000 shares) for the same period last year. 

Other Reported Information

Total sales in the medical market for the first quarter of fiscal 2015 were $7.2 million, an increase of 20 percent compared to the same period last year.  Total sales in the veterinary market for the first quarter of fiscal 2015 were $39.4 million, an increase of 8 percent, compared to the same period last year.  Total medical and veterinary reagent disc sales for the first quarter of fiscal 2015 were $26.9 million, an increase of 18 percent compared to the same period last year.  Total unit sales of medical and veterinary reagent discs for the first quarter of fiscal 2015 were 2.1 million units, an increase of 18 percent, compared to the same period last year.  Total medical and veterinary instrument sales for the first quarter of fiscal 2015 were $7.6 million, a decrease of 12 percent, compared to the same period last year.  Total unit sales of medical and veterinary instruments for the first quarter of fiscal 2015 were 1,077 units, a decrease of 12 percent, compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the first quarter of fiscal 2015 was $2.0 million, compared to $2.2 million for the same period last year.  Abaxis paid $2.2 million in cash dividends to shareholders during the first quarter of fiscal 2015. 

Clint Severson, chairman, president and chief executive officer of Abaxis, said, "We are pleased with the strong financial results achieved in both the veterinary and medical markets during the first quarter of fiscal 2015.  As a result of our strategic initiatives to work more closely with our distribution partners, we were able to produce strong revenue growth for the first quarter, led by 20% growth in medical sales and a solid 8% growth in veterinary sales.  We had strong unit sales of chemistry analyzers, with sales of VetScan VS2s increasing 30% and Piccolo Xpress increasing 20% during the quarter over last year's comparable quarter.  Additionally, revenues from consumable sales, the core strength of our business, increased 12% in the first quarter and 14% sequentially; accounting for 72% of total revenues for the quarter.  With an expanded installed base of chemistry analyzers and increased customer utilization of diagnostic reagent discs, we sold 2.1 million units during the first quarter.  Our improved operating performance allowed gross margin to grow 188 basis points to 50% over last year's comparable quarter.  The measurable success during the first quarter gives us confidence we will achieve improved operating results and return to growth in fiscal 2015."

"We enter fiscal 2015 focused on executing on organic growth, improving operating efficiencies, leveraging our distribution partnerships and capitalizing on opportunities with our recently announced supply and co-marketing agreement with VCA Inc.  We have the financial wherewithal to effectively grow our business going forward, with cash, cash equivalents and investments of $125.7 million at June 30, 2014.  Due to our strong cash flow profile and our positive outlook for the year, the Board of Directors has again approved a quarterly dividend in the amount of $0.10 per share of common stock, which we expect will be paid in September 2014.  We look forward to building momentum as we advance through fiscal 2015 and beyond," Mr. Severson concluded.

Conference Call

Abaxis has scheduled a conference call to discuss its financial results at 4:15 p.m. Eastern Time on Thursday, July 24, 2014.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet webcast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10049800, through July 30, 2014.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov

About Abaxis

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia and Lyme disease.  Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  For more information, visit http://www.abaxis.com.

Use of Financial Measures

To supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure.  The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.  For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

Forward Looking Statements

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to the transition of its U.S. medical sales to Abbott, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables to Follow

 

ABAXIS, INC.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)



Three Months Ended


June 30,


2014

2013

Revenues

$      47,477

$     43,169

Cost of revenues

23,605

22,277

Gross profit

23,872

20,892

Operating expenses:



   Research and development 

3,947

3,173

   Sales and marketing 

9,578

10,028

   General and administrative

2,908

3,055

Total operating expenses

16,433

16,256

Income from operations

7,439

4,636

Interest and other income (expense), net

47

404

Income before income tax provision

7,486

5,040

Income tax provision

2,771

1,811

Net income

$        4,715

$       3,229




Net income per share:



  Basic net income per share

$          0.21

$         0.15

  Diluted net income per share

$          0.21

$         0.14

Shares used in the calculation of net income per share:



  Weighted average common shares outstanding - basic

22,408

22,229

  Weighted average common shares outstanding - diluted

22,637

22,571

Cash dividends declared per share

$          0.10

$               -

 

ABAXIS, INC.

Condensed Consolidated Balance Sheets

(Unaudited and in thousands)



June 30, 

March 31,


2014

2014

Current assets:



 Cash and cash equivalents

$       87,103

$       73,589

 Short-term investments

20,139

29,102

 Receivables, net

33,252

29,227

 Inventories

27,553

26,978

 Prepaid expenses and other current assets

1,719

2,452

 Net deferred tax assets, current

5,190

4,464

   Total current assets 

174,956

165,812

Long-term investments

18,411

18,491

Investment in unconsolidated affiliate

2,597

2,646

Property and equipment, net

27,720

27,176

Intangible assets, net

1,249

1,624

Net deferred tax assets, non-current

1,549

1,557

Other assets

129

74

   Total assets

$     226,611

$     217,380




Current liabilities:



 Accounts payable

$         7,050

$         6,111

 Accrued payroll and related expenses

6,877

4,654

 Accrued taxes

3,525

1,144

 Other accrued liabilities

3,849

3,095

 Deferred revenue

1,188

1,208

 Warranty reserve

961

1,047

   Total current liabilities

23,450

17,259

Non-current liabilities:



 Deferred rent

768

768

 Deferred revenue

3,833

4,035

 Warranty reserve

912

821

 Notes payable, less current portion

556

581

   Total non-current liabilities

6,069

6,205

   Total liabilities

29,519

23,464

Shareholders' equity:



 Common stock

125,306

124,603

 Retained earnings 

71,787

69,318

 Accumulated other comprehensive loss

(1)

(5)

   Total shareholders' equity

197,092

193,916

   Total liabilities and shareholders' equity

$     226,611

$     217,380


The following table presents our calculation of operating income per share for the three months ended June 30, 2014 and 2013.

 

Operating Income Per Share

(In thousands, except per share data)



Three Months Ended


June 30,


2014

2013

Income from operations

$      7,439

$      4,636




Shares used in the calculation of operating income per share:



  Weighted average common shares outstanding - basic

22,408

22,229

  Weighted average common shares outstanding - diluted

22,637

22,571




Operating income per share - basic

$        0.33

$        0.21

Operating income per share - diluted

$        0.33

$        0.21

The following table presents our revenues by source for the three months ended June 30, 2014 and 2013.

 

Revenues by Geographic Region and Customer Group

(In thousands)



Three Months Ended


June 30,

Revenues by Geographic Region

2014

2013

North America

$      38,340

$      34,652

International

9,137

8,517

Total revenues

$      47,477

$      43,169





Three Months Ended


June 30,

Revenues by Customer Group

2014

2013

Medical Market

$        7,245

$        6,038

Veterinary Market

39,367

36,371

Other

865

760

Total revenues

$      47,477

$      43,169

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.